HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma.
Juan Yuan, Subhamita Maitra, Eirini Antoniou, Jiacheng Zhu, Wenyu Li, Ilknur Safak Demirel, Kostantinos Toskas, Iria Laura Martinez, Lacin Ozcimen, Henrik Lindehell, Jonas Muhr, Jakob J. E. Stenman, Per Kogner, Oscar C. Bedoya-Reina, Susanne Schlisio, Johan Holmberg
This paper shows that HIF2α reduces MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma, suggesting HIF2 has tumor suppressor rather than oncogenic function.
Proceedings of the National Academy of Sciences · Oct 21, 2025Peer-reviewedCancer Biology